ISPC יחס הלוואות לטווח ארוך להון iSpecimen Inc
iSpecimen Inc. is competing for contracts with pharma behemoths within the niche biospecimen segment. The long-term debt-to-equity ratio on the GURU.Markets terminal illustrates a chart of the metric, where the current value is 0.10. The company is developing AI-driven biomarker discovery through a unique data marketplace while adhering to standard environmental office management regulations.
%3A%20%D7%99%D7%97%D7%A1%20%D7%97%D7%95%D7%91%20%D7%9C%D7%98%D7%95%D7%95%D7%97%20%D7%90%D7%A8%D7%95%D7%9A%20%D7%9C%D7%94%D7%95%D7%9F%20%D7%A2%D7%A6%D7%9E%D7%99&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_ISPC_-_iSpecimen-Inc._-_Long-Term-Debt-to-Equity-Ratio "ISPC מקדם חוב לטווח ארוך להון iSpecimen Corp (04.07.2022 - 28.10.2026) | 👁️GURU.Markets👁️")
פילוחי מדדים ואנליטיקה של חברת iSpecimen Inc (ISPC)
Capital structure distinguishes sustainable business models from high-risk speculative assets. The asset-light marketplace format of iSpecimen Inc. (ISPC) minimizes the need for capital expenditures on biospecimen storage. This chart of long-term debt to equity measures the proportion of loans with maturities exceeding one year relative to net assets. This metric allows for an assessment of the IT core's dependence on borrowed funds. Low values confirm the company's financial autonomy and stability.